JP2002517185A - 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原 - Google Patents

前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原

Info

Publication number
JP2002517185A
JP2002517185A JP2000552152A JP2000552152A JP2002517185A JP 2002517185 A JP2002517185 A JP 2002517185A JP 2000552152 A JP2000552152 A JP 2000552152A JP 2000552152 A JP2000552152 A JP 2000552152A JP 2002517185 A JP2002517185 A JP 2002517185A
Authority
JP
Japan
Prior art keywords
tmprss2
protein
polynucleotide
prostate
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000552152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517185A5 (enExample
Inventor
ダニエル イー． エーファー
レーヌ エス． ヒュバート
カハン レオン
アーサー ビー． レイタノ
ダグラス シー． サフラン
ステファン チャペル ミッチェル
Original Assignee
アジェンシス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス，インコーポレイテッド filed Critical アジェンシス，インコーポレイテッド
Publication of JP2002517185A publication Critical patent/JP2002517185A/ja
Publication of JP2002517185A5 publication Critical patent/JP2002517185A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000552152A 1998-06-01 1999-06-01 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原 Withdrawn JP2002517185A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US60/087,598 1998-06-01
US9147498P 1998-06-29 1998-06-29
US60/091,474 1998-06-29
US12952199P 1999-04-14 1999-04-14
US60/129,521 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008330218A Division JP2009148265A (ja) 1998-06-01 2008-12-25 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原

Publications (2)

Publication Number Publication Date
JP2002517185A true JP2002517185A (ja) 2002-06-18
JP2002517185A5 JP2002517185A5 (enExample) 2005-12-22

Family

ID=27375711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000552152A Withdrawn JP2002517185A (ja) 1998-06-01 1999-06-01 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原
JP2008330218A Pending JP2009148265A (ja) 1998-06-01 2008-12-25 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008330218A Pending JP2009148265A (ja) 1998-06-01 2008-12-25 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原

Country Status (12)

Country Link
US (1) US20060275304A1 (enExample)
EP (1) EP1082341B1 (enExample)
JP (2) JP2002517185A (enExample)
AT (1) ATE490977T1 (enExample)
AU (2) AU773187B2 (enExample)
CA (1) CA2329137C (enExample)
CY (1) CY1111906T1 (enExample)
DE (1) DE69943020D1 (enExample)
DK (1) DK1082341T3 (enExample)
IL (1) IL139988A0 (enExample)
PT (1) PT1082341E (enExample)
WO (1) WO1999062942A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
EP1200590B1 (en) 1999-08-12 2009-01-07 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096538A2 (en) * 2000-06-13 2001-12-20 Bayer Aktiengesellschaft Regulation of human transmembrane serine protease
DE60138465D1 (de) * 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008119767A2 (en) * 2007-03-30 2008-10-09 Oryzon Genomics, S. A. Method of nucleic acid analysis.
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
KR102069397B1 (ko) * 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
AU675506B2 (en) * 1993-01-15 1997-02-06 Genetics Institute, Llc Cloning of enterokinase and method of use
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2281954A1 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
ATE490977T1 (de) 2010-12-15
IL139988A0 (en) 2002-02-10
AU773187B2 (en) 2004-05-20
EP1082341B1 (en) 2010-12-08
PT1082341E (pt) 2011-02-15
WO1999062942A2 (en) 1999-12-09
CA2329137C (en) 2011-09-20
DE69943020D1 (de) 2011-01-20
JP2009148265A (ja) 2009-07-09
EP1082341A2 (en) 2001-03-14
WO1999062942A3 (en) 2000-06-02
AU4413699A (en) 1999-12-20
AU2004202306B2 (en) 2007-05-24
DK1082341T3 (da) 2011-03-28
AU2004202306C1 (en) 2008-05-01
US20060275304A1 (en) 2006-12-07
CA2329137A1 (en) 1999-12-09
CY1111906T1 (el) 2015-11-04
AU2004202306A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
JP2009148265A (ja) 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原
US7981624B2 (en) Methods to detect tumors using 20P1F12/TMPRSS2 expression
AU775272B2 (en) 36P6D5: secreted tumor antigen
US8053551B2 (en) Serpentine transmembrane antigens expressed in human cancers and uses therefor
JP2010029209A (ja) Ｐｓｃａ：前立腺幹細胞抗原
EP1104462A2 (en) Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
JP2009148264A (ja) 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
AU764911B2 (en) PHELIX: a testis-specific protein expressed in cancer
AU2007209794B2 (en) Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
ES2356117T3 (es) Antígeno tumoral útil en el diagnóstico y la terapia de cáncer de colon y de próstata.
AU2006201736B2 (en) BPC-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
AU2003203703B2 (en) BPC-1:a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
CA2344563A1 (en) Methods and compositions for the diagnosis and therapy of prostate cancer
WO1999058560A2 (en) Prostapin gene and protein and uses thereof
AU2007203592A1 (en) 36P6D5: Secreted tumor antigen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070927

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090129